Trial evaluates maternal vaccine to protect newborns from Group B Streptococcus

Medical Xpress

Researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit at the University of the Witwatersrand (Wits) have played a leading role in an international phase 1/2 clinical trial demonstrating the safety and immunogenicity of an investigational maternal vaccine against Group B Streptococcus (GBS)—a major cause of life-threatening infections in newborns worldwide.

The findings have been published in Nature Medicine. ...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

Trial evaluates maternal vaccine to protect newborns from Group B Streptococcus

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

NASA Awards 2026 Innovative Technology Concepts

The oceans near Australia may be the best places to fertilize for removing carbon dioxide

Simple changes to fishing gear and handling can greatly improve survival of released coho salmon

Medical Xpress의 다른 기사

Consumption of ultra-processed foods by fathers may influence their babies' birth weight and body measurements

Blocking a mitochondrial transporter may curb inflammation from 'zombie' cells without killing them

In US veterans, rates of ALS associated with military branch and rank